- POSITIVE
Quarterly Revenue Shalby Jun-2026 Quarterly Revenue is Rs 259 Cr which is growth of 7.0% YoY.
- NEGATIVE
Quarterly Net Profit Shalby Jun-2026 Quarterly Net Profit is Rs 25 Cr which is growth of -2.4% YoY.
NSE: SHALBY | BSE: 540797
Shalby Live Share Price Today, Share Analysis and Chart
aboutShalby Ltd. is a multi-specialty healthcare provider and a global leader in joint replacement surgeries. Based in Ahmedabad, India, the company operates a network of multi-specialty hospitals and has diversified into the medical consumables and impla... Read More
120.64-1.32(-1.08%)
53,502
NSE+BSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Loading...
Mid-range PerformerThese stocks have affordable valuations, but mid range financials and momentumView SimilarEmbed DVM
Please subscribe to view forecaster data
Shalby Stock Price Analysis
Day Price Range-1.1% 1 Day return | 120.6 (LTP) 119.8122 LowHigh |
|---|---|
Week Price Range6.4% 1 Week return | 120.6 (LTP) 112126.9 LowHigh |
Month Price Range-9.7% 1 Month return | 120.6 (LTP) 110.6137.1 LowHigh |
52 Week Price Range-50.0% 1 Year return | 120.6 (LTP) 110.6252 LowHigh |
Competitors/Peers
Revenue Mix
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Shalby quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 259.1 | 230.5 | 221 | 229.8 | 242.2 | 214.2 | 226.9 | 217.6 | 240.2 | 210.7 | 200.4 | 223.1 | 216.4 | ||
Operating Exp. | 211.3 | 193.4 | 185.6 | 185 | 189.8 | 176.2 | 178.1 | 176.8 | 182.2 | 168.1 | 151.9 | 165.6 | 166.6 | |
Operating Profit | 42.5 | 31.5 | 29.6 | 39 | 46.8 | 30.8 | 42.5 | 35.5 | 50.5 | 38.3 | 43.2 | 51.5 | 44.5 | |
Operating Profit Margin % | 16.74% | 13.99% | 13.77% | 17.40% | 19.79% | 14.89% | 19.27% | 16.71% | 21.71% | 18.54% | 22.14% | 23.74% | 21.07% | |
Depr. | 10.8 | 10.5 | 10 | 9.9 | 9.7 | 9.6 | 9.9 | 9.8 | 9.5 | 9.1 | 9.3 | 9.4 | 9.2 | |
Interest | 3.1 | 2.4 | 3.6 | 4.3 | 2.6 | 2.7 | 3.1 | 2.7 | 2.7 | 1 | 0.6 | 0.7 | 0.6 | |
Profit Before Tax | 33.9 | 23.5 | 21.9 | 30.6 | 40.1 | 25.7 | 35.8 | 28.3 | 45.8 | 32.5 | 38.5 | 47.3 | 40 | |
Tax | 8.8 | -30.2 | 8.1 | 10.8 | 14.4 | 10.7 | 14.9 | 11 | 15.4 | 10 | 13.8 | 16.9 | 13.8 | |
Net Profit | 25.1 | 53.7 | 13.8 | 19.8 | 25.7 | 15 | 20.9 | 17.3 | 30.5 | 22.6 | 24.7 | 30.4 | 26.2 | |
EPS Adj. latest | 2.3 | 5 | 1.3 | 1.8 | 2.4 | 1.4 | 1.9 | 1.6 | 2.8 | 2.1 | 2.3 | 2.8 | 2.4 | |
Net profit TTM | 112.3 | 112.9 | 74.2 | 81.3 | 78.9 | 83.6 | 91.2 | 95.1 | 108.1 | 103.8 | 99.6 | 94.1 | 85.5 | |
Basic EPS TTM | 10.4 | 10.5 | 6.9 | 7.6 | 7.3 | 7.8 | 8.5 | 8.9 | 10.1 | 9.7 | 9.3 | 8.8 | 8 | |
Earnings Transcripts | ||||||||||||||
AI Summary | ||||||||||||||
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Shalby Technical Analysis
Shalby EMA & SMA
Bearish-6
1 bullish, 7 bearish
Bullish1
Bearish7
| 5 Day | 120.6 |
|---|---|
| 10 Day | 121.9 |
| 12 Day | 122.8 |
| 20 Day | 126.4 |
| 26 Day | 128.9 |
|---|---|
| 50 Day | 136.9 |
| 100 Day | 147.0 |
| 200 Day | 160.1 |
Shalby Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202650.4%
Week57.6%
Month58.1%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Shalby Resistance and Support
120.82
Pivot
| First Resistance | 121.8 |
|---|---|
| Second Resistance | 123.0 |
| Third Resistance | 124.0 |
| First Support | 119.7 |
|---|---|
| Second Support | 118.7 |
| Third Support | 117.5 |
| Day RSI | 36.7 |
|---|---|
| Day MACD | -6.1 |
| Day MFI | 25.7 |
| Day MACD Signal Line | -6.2 |
Shalby Beta
| 1 Month | 0.9 |
|---|---|
| 1 Year | 1.4 |
| 3 Month | 1.1 |
|---|---|
| 3 Year | 1.2 |
Shalby Price Change Analysis
↓-9.7%
Over 1 Month
LowHigh
110.6137.1
↓-25.2%
Over 3 Months
LowHigh
110.6169.0
↓-24.9%
Over 6 Months
LowHigh
110.6182.3
↓-50%
Over 1 Year
LowHigh
110.6252.1
Shalby Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 22 Sep 2025 | 266.55 | 1,354,105 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Purchase | 22 Sep 2025 | 266.34 | 1,354,105 | NSE |
| MUSIGMA SECURITIES | Bulk | Sell | 05 Sep 2025 | 223.36 | 548,438 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 05 Sep 2025 | 223.57 | 568,902 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Purchase | 05 Sep 2025 | 223.40 | 568,902 | NSE |
| MUSIGMA SECURITIES | Bulk | Purchase | 05 Sep 2025 | 223.24 | 548,438 | NSE |
| HARESH TIKAMDAS KASWANI | Block | Sell | 13 Jun 2025 | 180 | 700,000 | NSE |
| FIRST WATER FUND | Block | Purchase | 13 Jun 2025 | 180 | 700,000 | NSE |
| HARESH TIKAMDAS KASWANI | Bulk | Sell | 13 Jun 2025 | 180 | 700,000 | NSE |
| FIRST WATER FUND | Bulk | Purchase | 13 Jun 2025 | 180 | 700,000 | NSE |
Shalby Corporate Actions
Shalby Dividend history and yield
Shalby dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Shalby dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
119 Sep 2024 | 1.2 | FINAL | - | Equity Share |
208 Aug 2023 | 1.2 | FINAL | - | Equity Share |
319 Sep 2022 | 1 | FINAL | - | Equity Share |
417 Sep 2021 | 1 | FINAL | - | Equity Share |
504 Sep 2020 | 0.5 | FINAL | - | Equity Share |
Shalby Board Meetings
Shalby past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
103 Nov 2026 | Quarterly Results | - |
212 Aug 2026 | Quarterly Results | (Revised) |
327 May 2026 | Audited Results & Final Dividend | - |
411 Feb 2026 | Quarterly Results | - |
513 Nov 2025 | Quarterly Results | - |
Shalby Research Reports
Shalby research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 103 Nov 2024 | ICICI Direct | 310 | 226.38 | Buy | 36.94% | -46.71% | |
| 214 Jul 2024 | ICICI Direct Target | 350 | 284.4 | Buy | 23.07% | -57.58% | |
| 307 Apr 2024 | ICICI Direct | 320 | 282.1 | Buy | 13.43% | -57.24% | |
| 402 Apr 2024 | ICICI Direct Target | 320 | 262.7 | Buy | 21.81% | -54.08% | |
| 506 Dec 2023 | AUM Capital | 376 | 306.9 | Buy | 22.52% | -60.69% |
Shalby Corporate Filings
Shalby BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 28 Oct 2026 | Shalby Ltd - 540797 - Shalby Hospital, Jabalpur Is Now Fully Operational | Intimation u/r. 30 of SEBI LODR | |
| 23 Oct 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | Schedule of Earnings Conference Call to discuss Q2FY2027 earnings | |
| 22 Oct 2026 | Shalby Ltd - 540797 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For Period Ended On September 30, 2026 | Shalby Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Board Meeting Intimation | |
| 17 Oct 2026 | Shalby Ltd - 540797 - Withdrawal Of Suspension Of Registration Of Shalby Hospital, Jabalpur | Intimation u/r. 30 of SEBI LODR | |
| 14 Oct 2026 | Shalby Ltd - 540797 - Intimation U/R. 30 Of SEBI LODR | Intimation u/r. 30 of SEBI LODR |
Shalby Documents
Shalby Earnings Call
Shalby earnings calls, including management commentary and AI-generated summaries.
| Date | Title | Links |
|---|---|---|
| 19 Aug 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 13 Aug 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Link |
| 02 Jun 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 18 Feb 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 14 Aug 2025 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Link |
Shalby Annual Reports
Shalby financials, including annual results, balance sheets, and cash flow statements.
Shalby Credit Ratings
Shalby credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 26 Jul 2026 | icra ratings | Shalby Limited | Rating downgraded to [ICRA]A; outlook revised to Stable; rated amount enhanced | Link |
| 05 Jun 2025 | icra ratings | Shalby Limited | Update on Material Event; Rating reaffirmed and outlook revised from Stable to Negative | Link |
| 03 Mar 2025 | icra ratings | Shalby Limited | Ratings reaffirmed and assigned for enhanced amount | Link |
| 20 Mar 2024 | icra ratings | Shalby Limited | Update on Material Event | Link |
| 29 Jan 2024 | icra ratings | Shalby Limited | Update on Material Event | Link |
Shalby Investor Presentations
Shalby investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 12 Aug 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 27 May 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 11 Feb 2026 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 13 Nov 2025 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 13 Aug 2025 | Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
Shalby - Company Profile
Shalby Management Structure
Shalby management structure with salaries, total experience, and qualifications.
Shalby Board of Directors
Shalby Board of directors with salaries, total experience, and qualifications.
Website: www.shalby.org
About the company - Business Profile
Shalby Ltd. is a multi-specialty healthcare provider and a global leader in joint replacement surgeries. Based in Ahmedabad, India, the company operates a network of multi-specialty hospitals and has diversified into the medical consumables and implant manufacturing sectors. Shalby has performed over 1,75,000 joint replacement surgeries to date, establishing one of the largest arthroplasty centers globally.
Key Points
- Key Facts: Founded in 1994 and headquartered in Ahmedabad, Gujarat, Shalby Ltd. is led by Dr. Vikram Shah (Chairman and Managing Director). The company is listed on both the BSE and NSE.
- Operations and Resources: The company operates 11 multi-specialty hospitals and 4 single-specialty franchise units across 9 states in Western, Northern, and Central India. As of December 2025, it maintains a total bed capacity of 2,297, with 1,415 operational beds.
- Market and Significance: Shalby holds a significant market share in Arthroplasty (Joint Replacement), which contributes approximately 33%–36% of its hospital revenue. It also provides high-acuity services in Cardiac Sciences, Oncology, Neurology, and Nephrology.
- Business Model: Shalby operates a synergistic model combining multi-specialty healthcare services, an asset-light franchise model (SOCE - Shalby Orthopaedic Centre of Excellence), and a MedTech division (implant manufacturing).
- Revenue Breakdown (FY2025 Annual):
- Total Consolidated Revenue: ₹1,114.6 crore.
- Domestic Revenue: ₹1,050 crore.
- International Revenue: ₹64.6 crore.
- Segment Revenue (Q2 FY2026):
- Shalby Hospitals, Pharma & Franchise: 80.9% (₹234.5 crore).
- Shalby MedTech (Implants): 11.6% (₹33.7 crore).
- Shalby International (Delhi-NCR): 6.9% (₹19.9 crore).
- Geographical and Payor Mix:
- Payor Mix (Q3 FY2026): TPA/Insurance (35%), Self-Pay (35%), Government (30%).
- Geographic Focus: Stronghold in Gujarat and Rajasthan, with recent expansion into Delhi-NCR via the acquisition of PK Healthcare (Sanar International Hospital).
- Products and Technology: Key products include knee and hip implants manufactured through its MedTech division. The company utilizes advanced EBUS systems and radiotherapy machines. It has 24 ongoing clinical research trials and 42 in the pipeline as of Q4 FY2025.
- Operational Metrics (FY2025):
- In-patient Count: 56,788.
- Out-patient Count: 5,40,119.
- Occupancy Rate: 47% (on operational beds).
- ARPOB (Average Revenue Per Operating Bed): ₹41,377.
- ALOS (Average Length of Stay): 3.65 days.
- Subsidiaries: Key units include Shalby MedTech (formerly Mars Medical Devices), Shalby Advanced Technologies Inc. (USA), and Shalby Global Technologies (Singapore).
- Strategic Initiatives and Outlook: Shalby is focusing on a grow smart strategy, prioritizing asset utilization and high-acuity specialty hubs (Oncology, Transplants) over rapid physical expansion. Future growth is targeted through the SOCE franchise model and international medical tourism, particularly in the Delhi-NCR facility.
References
